Atom Therapeutics

Atom Therapeutics is a biopharmaceutical company oriented towards research and development, primarily focusing on the innovation of drugs for treating diseases in the fields of metabolism, inflammation, and cardiovascular health. The core team mainly consists of senior researchers from the United States and within China, possessing extensive and rich experience in innovative drug development. ABP-671, an innovative drug for treating gout, is one of the drugs currently under development. ABP-671 has entered global pivotal clinical trials. In completed clinical trials, ABP-671 demonstrated good efficacy, safety, and tolerability. A single daily dose of 2 mg of ABP-671 may exhibit efficacy equivalent to or better than the highest doses of benzbromarone (80 mg) and febuxostat (80 mg), with its efficacy lasting 24 hours a day. ABP-745, an innovative drug for multiple indications including acute gout treatment, is currently undergoing Phase II clinical trials in the United States and Australia. Other pipeline products are in the preclinical stage. In the future, Atom Therapeutics will introduce more Best-in-Class innovative drugs with independent intellectual property rights to the world, benefiting more patients globally.